他达拉非-话题@MedSci

#他达拉非#

16篇内容 | 1584人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2184676, encodeId=6ee621846e6ca, content=<a href='/topic/show?id=0bad820e112' target=_blank style='color:#2F92EE;'>#肺动脉高压#</a> <a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a> <a href='/topic/show?id=7eaf1106e30c' target=_blank style='color:#2F92EE;'>#马西腾坦#</a>, objectTitle=J Am Coll Cardiol：马西腾坦/他达拉非单片联合治疗肺动脉高压的随机试验, objectType=article, longId=811400, objectId=2e0b81140005, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221107/1667834912742_8252897.webp, objectUrl=/article/show_article.do?id=2e0b81140005, replyNumber=0, likeNumber=65, createdTime=2024-01-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=2e0b81140005, moduleTitle=J Am Coll Cardiol：马西腾坦/他达拉非单片联合治疗肺动脉高压的随机试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e0b81140005)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2118573, encodeId=94f921185e3ff, content=<a href='/topic/show?id=a7b116558d6' target=_blank style='color:#2F92EE;'>#Sotatercept#</a>治疗<a href='/topic/show?id=0bad820e112' target=_blank style='color:#2F92EE;'>#肺动脉高压#</a>3期临床试验达终点。从1995年以来已经陆续有10多款药物获批，机制上基本分成了几大类：前列环素及类似物（PGI2），包括<a href='/topic/show?id=c5fb10551674' target=_blank style='color:#2F92EE;'>#依前列醇#</a>Epoprostenol、<a href='/topic/show?id=b4c460222ae' target=_blank style='color:#2F92EE;'>#曲前列环素#</a>Treprostinil、<a href='/topic/show?id=e715256693b' target=_blank style='color:#2F92EE;'>#伊洛前列素#</a>Iloprost、<a href='/topic/show?id=f1a610551eb1' target=_blank style='color:#2F92EE;'>#司来帕格#</a><a href='/topic/show?id=ce571611593' target=_blank style='color:#2F92EE;'>#Selexipag#</a>等；<a href='/topic/show?id=8a4610551847' target=_blank style='color:#2F92EE;'>#磷酸二酯酶5抑制剂#</a>（PDE5），包括<a href='/topic/show?id=0a1b904e96c' target=_blank style='color:#2F92EE;'>#西地那非#</a>和<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a>等；<a href='/topic/show?id=aa073045525' target=_blank style='color:#2F92EE;'>#内皮素受体拮抗剂#</a>（ETA/ETB），包括<a href='/topic/show?id=60b864948f2' target=_blank style='color:#2F92EE;'>#波生坦#</a>、<a href='/topic/show?id=bf96458280c' target=_blank style='color:#2F92EE;'>#安立生坦#</a>、<a href='/topic/show?id=60de101462b2' target=_blank style='color:#2F92EE;'>#马昔腾坦#</a><a href='/topic/show?id=57fe1121e58' target=_blank style='color:#2F92EE;'>#Macitentan#</a>等；<a href='/topic/show?id=3add105519f0' target=_blank style='color:#2F92EE;'>#可溶性鸟苷酸环化酶激动剂#</a>（sGC），包括<a href='/topic/show?id=ae6b3228332' target=_blank style='color:#2F92EE;'>#利奥西呱#</a><a href='/topic/show?id=872515489a0' target=_blank style='color:#2F92EE;'>#Riociguat#</a>。Sotatercept在选择基线病情较轻患者的情况下，有效性数据与此前已获批的单药或联用方案对比并不占压倒性优势。<a href='/topic/show?id=60c232154fc' target=_blank style='color:#2F92EE;'>#创新药物#</a>, objectTitle=NEJM：Sotatercept治疗肺动脉高压3期临床试验达终点（STELLAR研究）, objectType=article, longId=762303, objectId=b491e6230331, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230309/1678386039378_4754896.png, objectUrl=/article/show_article.do?id=b491e6230331, replyNumber=0, likeNumber=159, createdTime=2023-03-10, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b491e6230331, moduleTitle=NEJM：Sotatercept治疗肺动脉高压3期临床试验达终点（STELLAR研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b491e6230331)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1457787, encodeId=8f76145e787c2, content=<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a>, objectTitle=Eur Urol Focus：勃起功能障碍患者对他达拉非的偏好超过了西地那非, objectType=article, longId=212397, objectId=22af21239e2f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22af21239e2f, replyNumber=0, likeNumber=76, createdTime=2021-06-08, rootId=0, userName=yangshch, userId=d26b5981715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22af21239e2f, moduleTitle=Eur Urol Focus：勃起功能障碍患者对他达拉非的偏好超过了西地那非, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22af21239e2f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1457786, encodeId=ad57145e7863e, content=<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a>, objectTitle= J Pak Med Assoc：每日一次使用他达拉非与按需使用的疗效评估是否有累积作用？, objectType=article, longId=192999, objectId=e93a19299969, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e93a19299969, replyNumber=0, likeNumber=68, createdTime=2020-04-27, rootId=0, userName=yangshch, userId=d26b5981715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e93a19299969, moduleTitle= J Pak Med Assoc：每日一次使用他达拉非与按需使用的疗效评估是否有累积作用？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e93a19299969)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1457785, encodeId=132e145e78569, content=<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a>, objectTitle=Int J Clin Pract：6个月观察研究中他达拉非每天一次治疗勃起功能障碍的持续性和有效性, objectType=article, longId=192994, objectId=ed35192994a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed35192994a9, replyNumber=0, likeNumber=127, createdTime=2020-04-27, rootId=0, userName=yangshch, userId=d26b5981715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed35192994a9, moduleTitle=Int J Clin Pract：6个月观察研究中他达拉非每天一次治疗勃起功能障碍的持续性和有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed35192994a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1457784, encodeId=3ab5145e78451, content=<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a>, objectTitle=Urology：他达拉非日用与按需治疗勃起功能障碍的功效, objectType=article, longId=192992, objectId=755d192992dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=755d192992dc, replyNumber=0, likeNumber=98, createdTime=2020-04-27, rootId=0, userName=yangshch, userId=d26b5981715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=755d192992dc, moduleTitle=Urology：他达拉非日用与按需治疗勃起功能障碍的功效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=755d192992dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1457783, encodeId=5491145e7835d, content=<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a>, objectTitle=Urol Int：他达拉非每日一次与按需使用对勃起功能障碍患者的疗效和安全性, objectType=article, longId=192984, objectId=d7821929846e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7821929846e, replyNumber=0, likeNumber=91, createdTime=2020-04-27, rootId=0, userName=yangshch, userId=d26b5981715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7821929846e, moduleTitle=Urol Int：他达拉非每日一次与按需使用对勃起功能障碍患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7821929846e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1457782, encodeId=452a145e782b5, content=<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a>, objectTitle=Sex Med：每日和按需使用他达拉非治疗勃起功能障碍的长期疗效和耐受性, objectType=article, longId=192980, objectId=65b21929803d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65b21929803d, replyNumber=0, likeNumber=69, createdTime=2020-04-27, rootId=0, userName=yangshch, userId=d26b5981715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65b21929803d, moduleTitle=Sex Med：每日和按需使用他达拉非治疗勃起功能障碍的长期疗效和耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65b21929803d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1457781, encodeId=6de4145e781d2, content=<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a>, objectTitle=Ann Rheum Dis：初始联合使用安立生坦和他达拉非治疗结缔组织病相关性肺动脉高压（CTD-PAH）, objectType=article, longId=190265, objectId=f699190265d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f699190265d6, replyNumber=0, likeNumber=100, createdTime=2020-03-20, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f699190265d6, moduleTitle=Ann Rheum Dis：初始联合使用安立生坦和他达拉非治疗结缔组织病相关性肺动脉高压（CTD-PAH）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f699190265d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1457780, encodeId=7a0a145e78069, content=<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a>, objectTitle=BMC Urol：他达拉非抑制非细菌性前列腺炎的炎症反应, objectType=article, longId=189444, objectId=cd62189444d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd62189444d5, replyNumber=0, likeNumber=74, createdTime=2020-03-07, rootId=0, userName=yangshch, userId=d26b5981715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd62189444d5, moduleTitle=BMC Urol：他达拉非抑制非细菌性前列腺炎的炎症反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd62189444d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1457779, encodeId=b8be145e779a3, content=<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a>, objectTitle=Transl Androl Urol：每日低剂量他达拉非治疗对阴茎勃起功能障碍患者抑郁影响的评估, objectType=article, longId=185111, objectId=2db11851114b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2db11851114b, replyNumber=0, likeNumber=73, createdTime=2019-12-25, rootId=0, userName=yangshch, userId=d26b5981715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2db11851114b, moduleTitle=Transl Androl Urol：每日低剂量他达拉非治疗对阴茎勃起功能障碍患者抑郁影响的评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2db11851114b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1457778, encodeId=c9c5145e778da, content=<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a>, objectTitle=Aquestive Therapeutics收到美国食品和药物管理局（FDA）关于他达拉非口服薄膜的完整回复信, objectType=article, longId=153908, objectId=b841153908a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b841153908a0, replyNumber=0, likeNumber=73, createdTime=2018-11-21, rootId=0, userName=yangshch, userId=d26b5981715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b841153908a0, moduleTitle=Aquestive Therapeutics收到美国食品和药物管理局（FDA）关于他达拉非口服薄膜的完整回复信, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b841153908a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1457777, encodeId=2954145e777bc, content=<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a>, objectTitle=Int J Impot Res：勃起和射精功能障碍糖尿病患者低剂量和高剂量他达拉非药物使用对比研究, objectType=article, longId=139625, objectId=2c9313962553, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c9313962553, replyNumber=0, likeNumber=103, createdTime=2018-06-02, rootId=0, userName=yangshch, userId=d26b5981715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c9313962553, moduleTitle=Int J Impot Res：勃起和射精功能障碍糖尿病患者低剂量和高剂量他达拉非药物使用对比研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c9313962553)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1457776, encodeId=c086145e77653, content=<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a>, objectTitle=NEJM：安贝生坦和他达拉非初始联合治疗肺动脉高压已见成效, objectType=article, longId=55405, objectId=d8585540525, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8585540525, replyNumber=0, likeNumber=85, createdTime=2015-08-28, rootId=0, userName=yangshch, userId=d26b5981715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8585540525, moduleTitle=NEJM：安贝生坦和他达拉非初始联合治疗肺动脉高压已见成效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8585540525)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1457775, encodeId=36d0145e77599, content=<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a>, objectTitle=Clin Cancer Res：他达拉非能增加头颈部鳞癌患者的肿瘤特性免疫, objectType=article, longId=46417, objectId=fe7e4641ed7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe7e4641ed7, replyNumber=0, likeNumber=87, createdTime=2015-02-01, rootId=0, userName=yangshch, userId=d26b5981715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe7e4641ed7, moduleTitle=Clin Cancer Res：他达拉非能增加头颈部鳞癌患者的肿瘤特性免疫, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe7e4641ed7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1457774, encodeId=9790145e7749b, content=<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a>, objectTitle=JAMA：他达拉非不改善前列腺癌放疗后勃起功能障碍, objectType=article, longId=33054, objectId=9ada3305464, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ada3305464, replyNumber=0, likeNumber=73, createdTime=2014-04-10, rootId=0, userName=yangshch, userId=d26b5981715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ada3305464, moduleTitle=JAMA：他达拉非不改善前列腺癌放疗后勃起功能障碍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ada3305464)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1457773, encodeId=a2cb145e773e4, content=<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a>, objectTitle=希爱力（他达拉非）治疗良性前列腺增生获准, objectType=article, longId=3191, objectId=b67331915b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b67331915b, replyNumber=0, likeNumber=93, createdTime=2011-10-17, rootId=0, userName=yangshch, userId=d26b5981715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b67331915b, moduleTitle=希爱力（他达拉非）治疗良性前列腺增生获准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b67331915b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

他达拉非

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#肺动脉高压# #他达拉非# #马西腾坦#

J Am Coll Cardiol：马西腾坦/他达拉非单片联合治疗肺动脉高压的随机试验

2024-01-29发表于上海

showtest (审核中...)

前往app查看评论内容

全文收起 #Sotatercept#治疗#肺动脉高压#3期临床试验达终点。从1995年以来已经陆续有10多款药物获批，机制上基本分成了几大类：前列环素及类似物（PGI2），包括#依前列醇#Epoprostenol、#曲前列环素#Treprostinil、#伊洛前列素#Iloprost、#司来帕格##Selexipag#等；#磷酸二酯酶5抑制剂#（PDE5），包括#西地那非#和#他达拉非#等；#内皮素受体拮抗剂#（ETA/ETB），包括#波生坦#、#安立生坦#、#马昔腾坦##Macitentan#等；#可溶性鸟苷酸环化酶激动剂#（sGC），包括#利奥西呱##Riociguat#。Sotatercept在选择基线病情较轻患者的情况下，有效性数据与此前已获批的单药或联用方案对比并不占压倒性优势。#创新药物#

NEJM：Sotatercept治疗肺动脉高压3期临床试验达终点（STELLAR研究）

2023-03-10发表于上海

yangshch (审核中...)

前往app查看评论内容

#他达拉非#

Eur Urol Focus：勃起功能障碍患者对他达拉非的偏好超过了西地那非

2021-06-08

yangshch (审核中...)

前往app查看评论内容

#他达拉非#

J Pak Med Assoc：每日一次使用他达拉非与按需使用的疗效评估是否有累积作用？

2020-04-27

yangshch (审核中...)

前往app查看评论内容

#他达拉非#

Int J Clin Pract：6个月观察研究中他达拉非每天一次治疗勃起功能障碍的持续性和有效性

2020-04-27

yangshch (审核中...)

前往app查看评论内容

#他达拉非#

Urology：他达拉非日用与按需治疗勃起功能障碍的功效

2020-04-27

yangshch (审核中...)

前往app查看评论内容

#他达拉非#

Urol Int：他达拉非每日一次与按需使用对勃起功能障碍患者的疗效和安全性

2020-04-27

yangshch (审核中...)

前往app查看评论内容

#他达拉非#

Sex Med：每日和按需使用他达拉非治疗勃起功能障碍的长期疗效和耐受性

2020-04-27

仁者大医 (审核中...)

前往app查看评论内容

#他达拉非#

Ann Rheum Dis：初始联合使用安立生坦和他达拉非治疗结缔组织病相关性肺动脉高压（CTD-PAH）

2020-03-20

yangshch (审核中...)

前往app查看评论内容

#他达拉非#

BMC Urol：他达拉非抑制非细菌性前列腺炎的炎症反应

2020-03-07

yangshch (审核中...)

前往app查看评论内容

#他达拉非#

Transl Androl Urol：每日低剂量他达拉非治疗对阴茎勃起功能障碍患者抑郁影响的评估

2019-12-25

yangshch (审核中...)

前往app查看评论内容

#他达拉非#

Aquestive Therapeutics收到美国食品和药物管理局（FDA）关于他达拉非口服薄膜的完整回复信

2018-11-21

yangshch (审核中...)

前往app查看评论内容

#他达拉非#

Int J Impot Res：勃起和射精功能障碍糖尿病患者低剂量和高剂量他达拉非药物使用对比研究

2018-06-02

yangshch (审核中...)

前往app查看评论内容

#他达拉非#

NEJM：安贝生坦和他达拉非初始联合治疗肺动脉高压已见成效

2015-08-28

yangshch (审核中...)

前往app查看评论内容

#他达拉非#

Clin Cancer Res：他达拉非能增加头颈部鳞癌患者的肿瘤特性免疫

2015-02-01

yangshch (审核中...)

前往app查看评论内容

#他达拉非#

JAMA：他达拉非不改善前列腺癌放疗后勃起功能障碍

2014-04-10

yangshch (审核中...)

前往app查看评论内容

#他达拉非#

希爱力（他达拉非）治疗良性前列腺增生获准

2011-10-17

科室
- - 订阅+
  - 更多科室
工具
服务